Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.

Détails

ID Serval
serval:BIB_10535
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.
Périodique
International Journal of Cancer
Auteur(s)
Marchand M., van Baren N., Weynants P., Brichard V., Dréno B., Tessier M.H., Rankin E., Parmiani G., Arienti F., Humblet Y., Bourlond A., Vanwijck R., Liénard D., Beauduin M., Dietrich P.Y., Russo V., Kerger J., Masucci G., Jäger E., De Greve J., Atzpodien J., Brasseur F., Coulie P.G., van der Bruggen P., Boon T.
ISSN
0020-7136
Statut éditorial
Publié
Date de publication
1999
Volume
80
Numéro
2
Pages
219-230
Langue
anglais
Notes
Publication types: Clinical Trial ; Controlled Clinical Trial ; Journal Article
Résumé
Thirty-nine tumor-bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE-3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one of these regressions involved cutaneous metastases. Three regressions were complete and 2 of these led to a disease-free state, which persisted for more than 2 years after the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) response was found in the blood of the 4 patients who were analyzed, including 2 who displayed complete tumor regression. Our results suggest that injection of the MAGE-3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced.
Mots-clé
Adult, Aged, Antigen Presentation, Antigens, Neoplasm/adverse effects, Antigens, Neoplasm/genetics, Disease Progression, Female, Genetic Code, HLA-A1 Antigen/immunology, Humans, Immunotherapy, Male, Melanoma/secondary, Melanoma/therapy, Middle Aged, Neoplasm Proteins/adverse effects, Neoplasm Proteins/genetics, Remission Induction/methods
Pubmed
Web of science
Open Access
Oui
Création de la notice
19/11/2007 13:00
Dernière modification de la notice
20/08/2019 13:37
Données d'usage